This happens because the expression of erythropoietin receptors (EpoR) on erythroid precursors decreases with maturation
Additional caution or monitoring may be appropriate in research settings involving: Pregnancy- or lactation-related research models, where limited safety data is available Active cancer-, tumor-, or abnormal proliferative research models, where NAD-related and metabolic-signaling pathways may influence cellular-signaling mechanisms Cardiovascular- or uncontrolled-hypertension research models, where metabolic-pathway modulation may influence cardiovascular-related biomarkers in some experimental settings Thyroid-related or endocrine research models, where metabolic-pathway investigations may influence endocrine-related observations Diabetes- or glucose-regulation research models, where insulin- and glucose-related pathways may warrant closer monitoring in experimental settings Moderate to severe hepatic- or renal-impairment research models, where compound metabolism or clearance mechanisms may be altered Autoimmune- or inflammatory-response research models, where immune-metabolic signaling pathways may influence inflammatory-related biomarkers or cytokine observations Research conditions, dosage ranges, administration frequency, protocol duration, and concurrent compounds may influence tolerability observations across experimental settings
No muscle loss was observed, indicating that weight reduction came specifically from fat tissue rather than lean body mass
FormBlends does not claim an individual clinician byline unless a named reviewer is available
The Australian biotech company Metabolic Pharmaceuticals (later Calzada) was founded to bring AOD-9604 to market
